01:05 PM EST, 12/10/2024 (MT Newswires) -- Chimerix ( CMRX ) plans to submit a new drug application before the end of the year for accelerated approval of dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma.

The stock price more than tripled Tuesday as intraday volume topped 153.7 million shares versus the daily average of almost 489,000.

UniQure ( QURE ) agreed with the US Food and Drug Administration on the elements of an accelerated approval pathway for its drug AMT-130, a potential treatment for Huntington's disease.

The stock price more than doubled as volume topped 48.9 million versus the daily average of almost 780,000.

Cumberland Pharmaceuticals ( CPIX ) said the FDA approved its supplemental new drug application for acetadote, simplifying the administration of the dosing regimen.

The shares surged 91% as volume topped 87.1 million versus the daily average of about 178,000.

Price: 2.71, Change: +1.84, Percent Change: +213.06